Navigation Links
Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities
Date:7/31/2012

PRINCETON, N.J., July 31, 2012 /PRNewswire/ -- Neura Therapeutik, LLC, a privately held specialty pharmaceutical company, announced today the formation of two strategic business units to capitalize on current and future opportunities in the analgesic market. The formation of Neura Group, LLC and Neura Labs, LLC structures the company to efficiently pursue commercial services, in-licensing, and joint venture opportunities in the analgesic marketplace.

Established by former King and Pfizer executives in 2010, Neura Therapeutik brings expertise in commercialization and development of analgesics, primarily in the NSAID and opioid classes of the pain market. Management's past experience includes directing pain franchise build outs and launching some of the largest US analgesic brands including Duragesic® patch and Vicodin ES® tablets. The formation of the business units allows Neura the ability to fully leverage its expertise in the analgesic market and build strong working alliances with strategic operational partners.

Through in-licensing and joint venture arrangements, the Neura Labs business unit will focus on establishing a portfolio of analgesic products with unique characteristics that fulfill unmet market needs, reside in the opioid and more specifically the tamper-resistant segment, or that have a high therapeutic index, or other unique pharmacokinetic or functional characteristics.

The Neura Group business unit provides companies interested in entering the analgesic market with a highly experienced turn-key commercial infrastructure and leadership team capable of rapidly establishing a total US operational presence. Neura Group offers best-in-class functional area expertise in CMC, regulatory and manufacturing scale-up to sales, marketing, launch readiness and lifecycle management.

"There are many nuances associated with analgesic commercialization. A commercial team with experience navigating the US analgesic marketplace is critical for the success of any product seeking to enter this market," said John La Lota, CEO of Neura Therapeutik. "Neura Therapeutik's two strategic business units provide an efficient solution to companies requiring an analgesic experienced commercial team whether they wish to retain the asset and leverage our commercial expertise, or if they seek an experienced company as a licensing partner."

Duragesic® is a registered trademark of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Vicodin ES® is a registered trademark of Abbott Laboratories.

Contact:

Neura Therapeutik, LLC
Greg Gironda: girondag@neuratherapeutik.com 
Visit: www.neuratherapeutik.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com


'/>"/>
SOURCE Neura Therapeutik, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
2. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
3. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Sanovas Forms Scientific Advisory Board to Support Development of Lung Cancer Technology
6. BioSurplus Forms New Division for Auction Services
7. Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
8. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
9. inVentiv Medical Management Forms Partnership with Vital Decisions
10. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
11. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
Breaking Medicine News(10 mins):